IQVIA schedules October 27 results for IQVIA Holdings stock

Published on 10/20/2026 at 20:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 sales rose 8.70 percent to USD 4.37 billion. IQVIA Holdings stock costs EUR 237.05 on October 20, 2026, down 0.77 percent versus the Xetra close.

Reporting date and market position

IQVIA scheduled its third-quarter results for October 27, 2026.
Second-quarter revenue rose 8.70 percent to USD 4.37 billion.
IQVIA Holdings stock costs EUR 237.05 at Lang & Schwarz on October 20, 2026 at 8:23 p.m. CEST, down 0.77 percent versus the Xetra close of October 20, 2026.
JPMorgan set a USD 295.00 target on October 14, 2026, 10.57 percent above the NYSE price.

NYSE Trading Floor mit aktiven Tradern und Healthcare-Sektor-Indexcharts auf Digitalanzeigen — IQVIA Holdings NYSE Börsenparkett US46266C1053 mit aktiven Tradern und Healthcare Sektor Indexcharts auf digitalen Anzeigetafeln, Illustration mit AI erstellt.

IQVIA scheduled its third-quarter 2026 results for October 27, 2026, before the market opens, according to IQVIA. The company also scheduled a conference call for 9:00 a.m. Eastern Time. After hours, IQVIA Holdings stock was trading at EUR 237.05 at Lang & Schwarz on October 20, 2026 at 8:23 p.m. CEST, down 0.77 percent versus the Xetra close of October 20, 2026 at EUR 238.90.

Second-quarter growth sets the baseline

IQVIA reported second-quarter 2026 revenue of USD 4.37 billion, up 8.70 percent from the year-earlier quarter. Adjusted earnings per share reached USD 3.15, an increase of 12.10 percent, while research and development solutions net new bookings rose 19.00 percent to USD 3.20 billion, according to Zacks on October 2, 2026.

Stock stays below the yearly high

The NYSE price was USD 266.81 at 2:29 p.m. EDT on October 20, 2026. IQVIA's 52-week range was USD 154.50 to USD 277.40, placing the stock 3.82 percent below its high. Market capitalization was USD 43.9 billion and the price-to-earnings ratio was 32.93 on the same date.

Analyst target and reporting date

JPMorgan maintained a Buy rating and raised its target from USD 285.00 to USD 295.00 in a report dated October 14, 2026, according to MarketScreener. The new target is 10.57 percent above the NYSE price cited above. The October 27 earnings release is the next dated corporate event, with the call scheduled for 9:00 a.m. Eastern Time.

Comparison with peers

IQVIA Holdings: down 0.77 percent versus the Xetra close, P/E 32.93, market capitalization USD 43.9 billion.

Charles River Laboratories (NYSE, USD): up 4.76 percent, P/E minus 64.87, market capitalization USD 15.1 billion as of October 20, 2026.

ICON (NYSE, USD): up 3.22 percent, P/E 40.55, market capitalization USD 13.4 billion as of October 20, 2026.

What the next report will test

The October 27 release will put the second-quarter growth rate against the company's full-year adjusted earnings guidance of USD 12.80 to USD 13.00 per share. For investors, the central comparison is whether bookings growth continues to translate into revenue while the valuation remains above 32 times earnings.

Price and reporting calendar

IQVIA Holdings stock was trading at EUR 237.05 at Lang & Schwarz on October 20, 2026 at 8:23 p.m. CEST, down 0.77 percent versus the Xetra close of October 20, 2026 at EUR 238.90. The further course of trading is shown by the continuously updated real-time quote of IQVIA Holdings stock.